Dicer Inhibits Hepatocellular Carcinoma by Inhibiting the Interleukin 6 Pathway

Background: Inflammatory cytokines are related to the occurrence and development of hepatocellular carcinoma (HCC). Objectives: Interleukin 6 (IL-6) is associated with prognosis HCC, while Dicer inhibits HCC; accordingly, we checked whether regulates HCC by modulating IL-6 pathway. Methods: The cells SMMC-7721 transfected overexpression (pCMV-Dicer) control (pCMV-NC) lentivirus were divided into 3 groups: SMMC-7721, pCMV-NC, pCMV-Dicer groups. assays cell proliferation, migration, invasion performed using counting, wound scratch, transwell chamber assay. level was measured flow cytometry bead-based immunoassays. All statistical analyses analyzed SPSS version 21 student t test 1-way analysis variance (ANOVA). Results: inhibited secretion from cells, as well growth invasion. incubation pCMV-NC increased proliferation (from 24 hours 72 hours; P < 0.05), migration (P = 0.008), 0.85). In addition, could reverse inhibitory effect on 0.01) 0.006) when incubated whereas an blocker tocilizumab enhance Dicer-induced inhibition 0.007), 0.001) cells. Furthermore, increase efficiency apatinib treatment their cooperation in downregulation. Conclusions: inhibit pathway, which would be a potential target for treatment. inducer might enhancer